Invetech Videos
-
The Current Challenges Facing Cell Therapy Manufacturing
2/26/2021
In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka explain the many current challenges associated with cell therapy manufacturing.
-
How Automation Drives Down Cell Therapy Manufacturing Costs
2/26/2021
In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka discussed how automation drives down manufacturing costs and the long road ahead to achieve continuous improvement.
-
Cell Therapy Manufacturing And Economies Of Scale
2/26/2021
In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka discussed why autologous and allogeneic therapies are, in fact, scalable as well as the hurdles and wins associated with achieving scalability.
-
Can Innovation Drive Down Cell Therapy Manufacturing Costs?
1/27/2021
The high cost of producing new cell and gene therapies is one of the largest issues facing the industry. After launching Kymriah and Yescarta, Novartis’ price tags were $475,000 and $375,000, respectively. Advancements in manufacturing are driving costs down, but not at the required pace.
-
3rd Generation Filling System Video
1/25/2021
3rd Generation Filling System is an automated bag filling platform for GMP manufacturing.
-
Cell And Gene Therapy Formulation And Fill Platform
1/25/2021
Solving commercial manufacturing challenges in cell and gene therapy.
-
Invetech 3rd Generation Filling System
1/21/2021
Invetech's 3rd generation filling system is an automated bag filling platform for GMP manufacturing. Watch this video to see a glimpse of the core capabilities of this system.
-
Automating Ancillary Processes: Closing Bottlenecks In CGT Manufacturing
Watch as speakers share a variety of challenges encountered when closing and automating ancillary processes, and how closed automated platforms improved scalability and reproducibility.
-
Transforming T Cell Manufacturing Via Elutriation With Korus
Learn about a system that uses a gentle elutriation process to give manufacturers a cleaner cell population to begin cell therapy production processes such as CAR-T.